Cell Therapy Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Cell Therapy Market Trends and Insights

Rising Approvals and Commercial Launches of Autologous CAR-T Therapies

The United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved nine new CAR-T indications between 2024 and 2025, reducing median review time from 14 months to 9 months ^{[1]U.S. Food and Drug Administration, “Approved Cellular and Gene Therapy Products,” fda.gov}. Novartis reported USD 680 million in 2025 revenue for Kymriah, reflecting 28% growth following label expansion to follicular lymphoma. European conditional approvals for three autologous T-cell receptor therapies in 2025 were the first for solid tumors, unlocking a USD 2.1 billion addressable segment by 2028. United States commercial payers linked 30–50% of reimbursement to six-month complete response rates across five CAR-T products in 2024, lowering upfront risk for hospitals. Japan’s regenerative-medicine fast-track designation halved review times for candidates with Phase 2 data showing ≥40% objective responses. 

Build-Out of Global CDMO Capacity for Allogeneic Pipelines

CDMOs installed 180,000 liters of allogeneic capacity from 2024 to 2025, including Lonza’s 50,000-liter Portsmouth facility and Charles River’s 40,000-liter Leiden site. Off-the-shelf platforms now generate a therapy batch within 48 hours, down from 4-6 weeks for autologous processes, and the cost-of-goods dropped from USD 350,000 to USD 75,000 per dose. Allogene Therapeutics’ ALPHA2 candidate delivered 67% complete remission in large B-cell lymphoma and targets a U.S. biologics license filing by mid-2026. Vertex and CRISPR Therapeutics committed USD 420 million to a Swiss base-edited T-cell plant, aiming for 100,000 annual doses by 2028. Samsung Biologics’ USD 300 million Incheon facility secured four regional contracts, signaling Asia-Pacific supply-chain localization. 

Expansion of National Reimbursement Pathways

Germany’s NUB pathway allowed hospitals to bill three allogeneic candidates ahead of full health-technology assessment, accelerating revenue capture by up to 24 months. Medicare’s NTAP program added 11 cell therapies in 2025, with USD 80,000–200,000 per-case top-ups that eased provider economics. Japan’s conditional reimbursement pathway enabled formulary entry with Phase 2 data in 2024 on the condition of seven-year post-market surveillance. South Korea priced two locally manufactured CAR-Ts at 40% below U.S. list levels, opening access to 1,200 patients annually. The United Kingdom’s final National Institute for Health and Care Excellence (NICE) guidance unlocked GBP 120 million in National Health Service funding for second-line large B-cell lymphoma in 2025.

AI-Optimized Closed Bioreactor Systems Cutting COGs Greater Than 40%

Lonza’s Cocoon platform delivered a 42% per-dose cost reduction for autologous CAR-T production compared with open systems by automating glucose feeds and oxygen control ^{[2]Lonza Group, “Q2 2025 Earnings Transcript,” lonza.com}. Machine-learning algorithms trained on 18,000 runs predicted cell viability with 94% accuracy, lowering batch-failure rates to 2%. Kite Pharma trimmed vein-to-vein time for Yescarta from 27 days to 16 days after four U.S. sites adopted automated lines in 2024. Fate Therapeutics hit USD 50,000 cost-of-goods per dose for iPSC-derived NK cells via 21-day continuous perfusion. The FDA recognized AI-controlled bioreactors as compliant process-analytical technology in 2025, allowing post-approval algorithm updates without fresh filings.

High Cost-of-Goods for Personalized Autologous Batches

Autologous CAR-T production averaged USD 350,000 per dose in 2025, driven by patient-specific apheresis, viral-vector transduction, and two-week expansion cycles. Yescarta’s average selling price fell 18% between 2023 and 2025 under outcomes-based contracts, trimming gross margin from 82% to 71%. German and French payers introduced EUR 100,000 per QALY thresholds in 2024, forcing 35% confidential discounts and squeezing profitability. High fixed costs of USD 12 million annually per GMP suite undermine scale for therapies addressing fewer than 500 patients per year. Limited affordability in middle-income countries, where per-capita health spending is below USD 2,000, restricts diffusion and caps revenue growth potential.

Viral-Vector and Plasmid Supply-Chain Bottlenecks

Lentiviral-vector shortages delayed 11 Phase 2 cell-therapy trials in 2024, stretching lead times from 16 weeks in 2022 to 32 weeks in 2024. Thermo Fisher reported a USD 1.8 billion services backlog in Q1 2025 and added 20,000 liters of extra capacity slated for Q4 2026 to ease constraints. Plasmid DNA lead times exceeded 24 weeks in 2024, with 40% price inflation year-over-year. FDA guidance in July 2024 supported non-viral electroporation and lipid-nanoparticle methods for early-phase trials, and six sponsors adopted these approaches by year-end FDA.GOV. Lonza and Catalent committed USD 1.1 billion to viral-vector expansion in 2024, but analysts project a 30% supply deficit through 2028.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

Therapy Type: Allogeneic Platforms Reshape Manufacturing Economics

Autologous products held 91.3% of the cell therapy market share in 2025, supported by mature CAR-T franchises and established reimbursement pathways. However, the allogeneic segment is advancing at a 17.34% CAGR through 2031 as off-the-shelf availability removes the 4-6 week manufacturing wait, lowers cost-of-goods to USD 75,000, and streamlines logistics.

Investor confidence intensified in 2025 when Vertex and CRISPR Therapeutics backed a Swiss plant designed for 100,000 doses annually, underscoring the scalability edge of allogeneic platforms. Regulatory flexibility, such as FDA acceptance of non-viral transfection, has shortened timelines, while outcomes-based contracting is tightening margins for autologous players. Allogeneic candidates, therefore, position the cell therapy market for cost-efficient penetration into less-affluent geographies without sacrificing margin integrity.

By Cell Type: Stem Cells Gain on Immune Platforms

Immune-cell therapies dominated 56.1% revenue in 2025, largely from CAR-T and tumor-infiltrating lymphocyte programs endorsed by strong oncology data. Stem-cell platforms are expanding at an 18.32% CAGR as mesenchymal and induced pluripotent stem-cell (iPSC) candidates demonstrate efficacy in cardiovascular and neurological disorders.

Mesoblast’s Phase 3 heart-failure trial cut major adverse events by 34%, while Takeda’s iPSC cardiomyocytes are enrolling ischemic patients with the first readout expected in 2026. Breakthroughs in scaffold and 3D-printing technologies are further elevating stem-cell momentum, positioning them as the cell therapy market’s diversification engine beyond hematologic malignancies.

By Application: Neurological Disorders Outpace Oncology Growth

Oncology delivered 39.3% revenue in 2025, yet neurological disorders are the fastest-growing application, posting a 17.47% CAGR through 2031, thanks to iPSC-derived dopaminergic neuron programs that achieved 32% Unified Parkinson’s Disease Rating Scale motor improvement at 12 months. Autoimmune indications also gained traction as systemic lupus erythematosus entered late-stage evaluation with 73% remission.

Cardiovascular, orthopedic, and ophthalmology segments are emerging as next-wave opportunities on the strength of mesenchymal, chondrocyte, and retinal-cell trials. These trends diversify the cell therapy market size base, lowering reliance on oncology and smoothing revenue volatility linked to competitive saturation in B-cell malignancies.

By End User: Specialized Centers Scale Faster Than Hospitals

Hospitals and clinics accounted for 65.2% of 2025 outlays, but specialized cell-and-gene centers are scaling at an 18.08% CAGR by standardizing apheresis, cryopreservation, and post-infusion care. Mayo Clinic’s 12-bed unit treated 180 patients in its first year and reduced cytokine-release-syndrome admissions to 4%, versus a 12% national benchmark.

Academic institutes drive Phase 1-2 innovation, while CDMOs provide industrialized capacity that underpins the cell therapy market size for allogeneic pipelines. High hospital utilization rates of 85% in top U.S. centers create bottlenecks, amplifying the strategic value of purpose-built facilities.

Geography Analysis

North America recorded a 54.2% share in 2025, with NTAP covering USD 80,000-200,000 per case and five commercial insurers shifting 30-50% payment to outcome-based models. Approvals rose to nine indications for CAR-T therapy between 2024-2025, and Yescarta revenue grew 22% to USD 2.1 billion. High apheresis-suite utilization at 85% created 6-8-week waits, underscoring capacity constraints.

Europe held a 28% share as Germany’s NUB pathway accelerated billing for three allogeneic therapies, while NICE guidance released GBP 120 million in U.K. funding. Conditional approvals for T-cell receptors targeting solid tumors opened a USD 2.1 billion European opportunity. However, QALY thresholds introduced in 2024 require an average of 35% discounts, tempering revenue expansion.

Asia-Pacific registered the fastest 17.89% CAGR; China’s first domestic CAR-T approval, Carvykti, addressed 2,500 multiple-myeloma patients in year one. Japan’s conditional reimbursement route accepted Phase 2 data with a mandatory seven-year follow-up. South Korea reimbursed two local CAR-Ts at 40% lower prices, serving 1,200 patients in 2025. Supply-chain localization via Samsung Biologics and growing CDMO capacity are consolidating the region as the cell therapy market’s next growth engine.

Regulatory Landscape

In the United States, the FDA has continued to formalize flexibility for chemistry, manufacturing, and controls (CMC) requirements that are central to cell therapy scale-up. In 2026, the agency advanced this stance through CMC-focused guidance activity (including draft and updated guidance) and related frameworks for human cellular and gene therapy products. This reinforces regulator tolerance for risk-based approaches in early development, while post-approval oversight remains anchored on process controls and product comparability.

In Europe, cell therapies are regulated as advanced therapy medicinal products (ATMPs) under the EMA framework, with ongoing CAT activity shaping expectations for development and lifecycle management. The EMA authorized ATMPs across 2025 and into 2026, and the European Commission withdrawal of Alofisel in December 2024 underscores active post-authorization lifecycle actions alongside new approvals. Separately, EMA CAT discussions in early 2026 referenced workstreams such as the IPRP Roadmap, indicating continued efforts toward regulatory convergence and reduced duplication for global submissions in gene and cell therapy.

Value Chain Analysis

The cell therapy value chain begins with donor or patient identification and clinical collection, including apheresis and tissue procurement. It then moves through critical raw materials (leukopaks, media, cytokines, viral vectors, plasmid DNA) and consumables used in GMP manufacturing. Manufacturing is executed either in-house or via CDMOs, with the market increasingly splitting into autologous, patient-specific batch workflows and allogeneic, scale-oriented campaigns.

Downstream steps include fill-finish (where applicable), cryopreservation and controlled storage, and chain-of-identity or chain-of-custody documentation. Distribution back to hospitals, clinics, and specialized cell-and-gene centers depends on time- and temperature-sensitive logistics for administration and follow-up. Bottlenecks persist at apheresis capacity, viral vector and plasmid availability, and coordination across multi-site programs, which increases vein-to-vein risk for autologous therapies. Industry responses focus on more integrated, end-to-end operating models that combine manufacturing, biostorage, and logistics under fewer handoffs, supported by digital tracking to manage parallel personalized lots. Capacity additions for allogeneic manufacturing, including the 180,000 liters added by CDMOs during 2024-2025, and logistics expansions such as Cryoport Systems opening a new Global Supply Chain Center in Southern California in May 2026, reflect positioning around reliability and orchestration as much as capacity.

Market Opportunities and Future Outlook

Manufacturing footprint expansion and automation-led standardization are creating whitespace in cost, throughput, and geographic access, particularly for allogeneic and iPSC-derived platforms that depend on repeatable, industrial-scale processes. The evidence for this investment cycle includes Johnson and Johnson announcing a more than USD 1 billion next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania (February 2026), FUJIFILM Cellular Dynamics opening a new iPSC development and manufacturing headquarters in Madison, Wisconsin designed to quadruple iPSC capacity (May 2026), and Orca Bio adding East Coast manufacturing capacity in Princeton, New Jersey to complement existing Sacramento operations (June 2026). These moves target constraints that slow commercial rollout, including lead times, regional supply resilience, and the ability to serve more sites with consistent product.

Regulatory and supply-chain enabling actions also support new execution pathways for platforms and suppliers that reduce friction in CMC and critical inputs. The FDA finalized guidance on CMC flexibilities for cell and gene therapy products in 2026 and is running initiatives such as the Manufacturing PreCheck Pilot Program, which included Cellares (June 2026), to support earlier alignment on manufacturing readiness for advanced and automated platforms. On inputs, expansions such as Sartorius Stedim Biotech opening a EUR 140 million competence center in Freiburg, Germany for critical cell therapy components like cytokines (May 2026) and Kincell Bio expanding its Research Triangle Park facility with added ISO 7 cleanroom suites (April 2026) point to a growing addressable market for specialized materials, GMP capacity, and integrated services that reduce the timeline from late-stage development into commercial supply.